James S. Turley
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Northrop Grumman: Demand Intact Despite Softer Sentiment. Morgan Stanley notes that aerospace and defense demand remains steady as the company heads into earnings, even though market sentiment has eased. Northrop Grumman is expanding its supplier network through the ANH Structure and LITEF, and its precision weapons business could help sustain growth. The company’s valuation is below that of competitor Anduril, adding context to the sector’s competitive landscape.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Mizuho Maintains Outperform on Emerson Electric, Raises Target. Mizuho maintained its Outperform rating on Emerson Electric and raised its price target to $180, showing continued analyst support. This action reflects the broader bullish Wall Street sentiment surrounding the company. In the wider industrial sector, peer firms like Eaton and Dover are also drawing attention as market participants evaluate their respective positions.
Transaction History
| C | ▲ Buy | Grant | 6 | $854 | 10/1/2026 | View on chart |
| C | ▲ Buy | Grant | 201 | $26K | 10/1/2026 | View on chart |
| C | ▲ Buy | Grant | 165 | $24K | 7/1/2026 | View on chart |
| C | ▲ Buy | Grant | 5 | $762 | 7/1/2026 | View on chart |
| NOC | ▲ Buy | Grant | 349 | $193K | 5/20/2026 | View on chart |
| C | ▲ Buy | Grant | 7 | $758 | 4/1/2026 | View on chart |
| C | ▲ Buy | Grant | 211 | $23K | 4/1/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 71,839 | — | 3/13/2026 | View on chart |
| PGEN | ▲ Buy | Grant | 17,806 | $62K | 3/10/2026 | View on chart |
| EMR | ▲ Buy | Grant | 1,251 | — | 2/3/2026 | View on chart |
| C | ▲ Buy | Grant | 11 | $1K | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 185 | $22K | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 1,263 | $0 | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 13 | $1K | 10/1/2025 | View on chart |
| C | ▲ Buy | Grant | 214 | $22K | 10/1/2025 | View on chart |
| C | ▲ Buy | Grant | 14 | $1K | 7/1/2025 | View on chart |
| C | ▲ Buy | Grant | 243 | $20K | 7/1/2025 | View on chart |
| NOC | ▲ Buy | Grant | 385 | $182K | 5/21/2025 | View on chart |
| C | ▲ Buy | Grant | 16 | $1K | 4/1/2025 | View on chart |
| C | ▲ Buy | Grant | 279 | $20K | 4/1/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 87,412 | — | 3/14/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 35,919 | $62K | 3/13/2025 | View on chart |
| EMR | ▲ Buy | Grant | 1,476 | — | 2/4/2025 | View on chart |
| C | ▲ Buy | Grant | 2,118 | $0 | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 24 | $2K | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 259 | $18K | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 295 | $18K | 10/1/2024 | View on chart |
| C | ▲ Buy | Grant | 27 | $2K | 10/1/2024 | View on chart |
| NOC | ▲ Buy | Grant | 377 | $183K | 7/31/2024 | View on chart |
| C | ▲ Buy | Grant | 275 | $17K | 7/1/2024 | View on chart |
| C | ▲ Buy | Grant | 25 | $2K | 7/1/2024 | View on chart |
| C | ▲ Buy | Grant | 273 | $17K | 4/1/2024 | View on chart |
| C | ▲ Buy | Grant | 25 | $2K | 4/1/2024 | View on chart |
| PGEN | ▲ Buy | Grant | 43,706 | $62K | 3/14/2024 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 106,837 | — | 3/9/2024 | View on chart |
| EMR | ▲ Buy | Grant | 1,867 | — | 2/6/2024 | View on chart |
| C | ▲ Buy | Grant | 265 | $14K | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 61 | $3K | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 2,923 | $0 | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 329 | $13K | 10/1/2023 | View on chart |
| C | ▲ Buy | Grant | 75 | $3K | 10/1/2023 | View on chart |
| C | ▲ Buy | Grant | 276 | $13K | 7/1/2023 | View on chart |
| C | ▲ Buy | Grant | 63 | $3K | 7/1/2023 | View on chart |
| NOC | ▲ Buy | Grant | 392 | $175K | 5/17/2023 | View on chart |
| C | ▲ Buy | Grant | 276 | $13K | 4/1/2023 | View on chart |
| C | ▲ Buy | Grant | 63 | $3K | 4/1/2023 | View on chart |
| PGEN | ▲ Buy | Grant | 53,418 | $62K | 3/9/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 61,576 | — | 2/22/2023 | View on chart |
| EMR | ▲ Buy | Grant | 1,933 | — | 2/7/2023 | View on chart |
| C | ▲ Buy | Grant | 3,353 | $0 | 1/3/2023 | View on chart |
| C | ▲ Buy | Grant | 246 | $11K | 1/1/2023 | View on chart |
| C | ▲ Buy | Grant | 54 | $2K | 1/1/2023 | View on chart |
| C | ▲ Buy | Grant | 226 | $11K | 10/1/2022 | View on chart |
| C | ▲ Buy | Grant | 49 | $2K | 10/1/2022 | View on chart |
| C | ▲ Buy | Grant | 220 | $11K | 7/1/2022 | View on chart |
| C | ▲ Buy | Grant | 48 | $2K | 7/1/2022 | View on chart |
| NOC | ▲ Buy | Grant | 385 | $175K | 5/18/2022 | View on chart |
| C | ▲ Buy | Grant | 194 | $11K | 4/1/2022 | View on chart |
| C | ▲ Buy | Grant | 22 | $1K | 4/1/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 16,212 | — | 3/25/2022 | View on chart |
| PGEN | ▲ Buy | Grant | 30,788 | $62K | 2/22/2022 | View on chart |
| C | ▲ Buy | Grant | 2,255 | $0 | 2/10/2022 | View on chart |
| EMR | ▲ Buy | Grant | 1,905 | — | 2/1/2022 | View on chart |
| C | ▲ Buy | Grant | 158 | $10K | 1/1/2022 | View on chart |
| C | ▲ Buy | Grant | 36 | $2K | 1/1/2022 | View on chart |
| C | ▲ Buy | Grant | 138 | $10K | 10/1/2021 | View on chart |
| C | ▲ Buy | Grant | 32 | $2K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
US presses China on Citigroup market access in Bangkok talks
The U.S. government has raised concerns about Citigroup's market access in China during bilateral talks in Bangkok. This diplomatic development highlights the ongoing regulatory and geopolitical risks associated with the bank's international operations. While Citi also initiated coverage on other companies like Mobileye, the trade discussions are the primary factor affecting the stock's broader outlook.
US presses China on Citigroup market access in Bangkok talks. The U.S. government has raised concerns about Citigroup's market access in China during bilateral talks in Bangkok. This diplomatic development highlights the ongoing regulatory and geopolitical risks associated with the bank's international operations. While Citi also initiated coverage on other companies like Mobileye, the trade discussions are the primary factor affecting the stock's broader outlook.